Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
نویسنده
چکیده
The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.
منابع مشابه
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
PURPOSE This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained after 5 years o...
متن کاملLarge registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Additional malignancies in multiple myeloma patients after first-line and maintenance treatment have been observed, questioning whether specific risks exist. Second primary malignancies have also gained attention since randomized data showed associations to newer drugs. We have conducted this large registry analysis in 744 consecutive patients and analyzed: 1) frequency and onset of additional ...
متن کاملSecond malignancies after multiple myeloma: from 1960s to 2010s.
Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients treated with lenalidomide as maintenance (vs placebo). This fact has prompted concern and highlighted the association between multiple myeloma and second malignancies. Furthermore, an excess of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) a...
متن کاملTherapy-Related Myeloid Malignancies in
Therapy related myeloid malignancies are an increasingly recognized treat complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenal antimyeloma agents in the context of therapy related myeloid malignanci...
متن کاملدرگیری پستان در فرد مبتلا به بیماری مولتیپل میلوما: گزارش موردی
In this paper, we report a rare case who is a twenty-six years old woman with extramedullary organ involvement of multiple myeloma. The initiation of disease was solitary plasmacytoma in the second vertebra of the lumbar spine that received radical radiotherapy and then she underwent chemotherapy for one year with the diagnosis of multiple myeloma after expanding lesion to the bones and adjacen...
متن کامل